Lobular breast cancer and breast-conserving surgery – risk of reoperations, residual cancer cells and local recurrence

Invasive lobular carcinoma in the breast and its association with residual cancer in re-excisions and locoregional recurrence

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN12077301

Enrollment

871

Registered

2024-09-04

Start date

2015-01-01

Completion date

Unknown

Last updated

2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female breast cancer patients undergoing breast-conserving surgery Cancer

Interventions

All female patients undergoing breast-conserving surgery at Skåne University Hospital Malmö due to in situ or invasive breast cancer from 1 January 2015 to 31 December 2016 will be included as study p

Eligibility

Sex/Gender

Female

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Female patients >18 years 2. Breast-conserving surgery as a primary surgical procedure 3. Final diagnosis of invasive or in situ cancer of the breast

Exclusion criteria

Exclusion criteria: 1. Male patients 2. Primary surgery not coded as breast-conserving surgery 3. Neoadjuvant treated 4. Benign final pathology result

Design outcomes

Primary

Measure	Time frame
Locoregional recurrence-free interval. Time to event will be defined from the date of first surgical intervention of primary breast cancer to the date of diagnosis of locoregional recurrence or the last day of follow-up in case of no locoregional recurrence. The locoregional recurrence-free interval will be presented for the whole cohort and stratified by the primary invasive cancer of no special type, invasive lobular carcinoma and ductal carcinoma in situ and the number of re-excisions. Data sources include medical records and the NKBC registry.	—

Measure

Time frame

Locoregional recurrence-free interval. Time to event will be defined from the date of first surgical intervention of primary breast cancer to the date of diagnosis of locoregional recurrence or the last day of follow-up in case of no locoregional recurrence. The locoregional recurrence-free interval will be presented for the whole cohort and stratified by the primary invasive cancer of no special type, invasive lobular carcinoma and ductal carcinoma in situ and the number of re-excisions. Data sources include medical records and the NKBC registry.

—

Secondary

Measure	Time frame
1. The proportion of patients of all primary breast cancer and/or in situ cancers with involved margins at first surgical intervention who will undergo no, one or multiple additional surgeries. The proportion of patients with residual cancer cells in their additional excised specimen as well as the final type of breast surgery (BCS or mastectomy) will also be recorded. Data sources include medical records. 2. Distant recurrence-free interval. Time to event will be defined from the date of first surgical intervention of primary breast cancer to the date of diagnosis of distant recurrence or the last day of follow-up in case of no distant recurrence. Distant recurrence-free interval will be presented for the whole cohort and stratified by the primary invasive cancer of no special type, invasive lobular carcinoma and ductal carcinoma in situ and the number of re-excisions. Data sources include medical records and the NKBC registry. 3. Breast cancer-specific survival. Time to event will be defined as the date of first surgical intervention of primary breast cancer to the date of breast cancer death, date of death from any other cause or date of database lock down for patients still alive. Breast cancer-specific survival will be presented for the whole cohort and stratified by the primary invasive cancer of no special type, invasive lobular carcinoma and ductal carcinoma in situ and the number of re-excisions. Data sources include medical records and the NKBC registry.	—

Measure

Time frame

1. The proportion of patients of all primary breast cancer and/or in situ cancers with involved margins at first surgical intervention who will undergo no, one or multiple additional surgeries. The proportion of patients with residual cancer cells in their additional excised specimen as well as the final type of breast surgery (BCS or mastectomy) will also be recorded. Data sources include medical records. 2. Distant recurrence-free interval. Time to event will be defined from the date of first surgical intervention of primary breast cancer to the date of diagnosis of distant recurrence or the last day of follow-up in case of no distant recurrence. Distant recurrence-free interval will be presented for the whole cohort and stratified by the primary invasive cancer of no special type, invasive lobular carcinoma and ductal carcinoma in situ and the number of re-excisions. Data sources include medical records and the NKBC registry. 3. Breast cancer-specific survival. Time to event will be defined as the date of first surgical intervention of primary breast cancer to the date of breast cancer death, date of death from any other cause or date of database lock down for patients still alive. Breast cancer-specific survival will be presented for the whole cohort and stratified by the primary invasive cancer of no special type, invasive lobular carcinoma and ductal carcinoma in situ and the number of re-excisions. Data sources include medical records and the NKBC registry.

—

Countries

Sweden

Contacts

Public ContactAnna Allfelt

anna.allfelt@med.lu.se+46 (0)709994204

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 17, 2026